786 related articles for article (PubMed ID: 15836565)
1. Botulinum toxin type A (BOTOX) for the prophylactic treatment of chronic daily headache: a randomized, double-blind, placebo-controlled trial.
Mathew NT; Frishberg BM; Gawel M; Dimitrova R; Gibson J; Turkel C;
Headache; 2005 Apr; 45(4):293-307. PubMed ID: 15836565
[TBL] [Abstract][Full Text] [Related]
2. Botulinum toxin type a for the prophylaxis of chronic daily headache: subgroup analysis of patients not receiving other prophylactic medications: a randomized double-blind, placebo-controlled study.
Dodick DW; Mauskop A; Elkind AH; DeGryse R; Brin MF; Silberstein SD;
Headache; 2005 Apr; 45(4):315-24. PubMed ID: 15836567
[TBL] [Abstract][Full Text] [Related]
3. Botulinum toxin type a prophylactic treatment of episodic migraine: a randomized, double-blind, placebo-controlled exploratory study.
Aurora SK; Gawel M; Brandes JL; Pokta S; Vandenburgh AM;
Headache; 2007 Apr; 47(4):486-99. PubMed ID: 17445098
[TBL] [Abstract][Full Text] [Related]
4. Botulinum toxin type A for the prophylactic treatment of chronic daily headache: a randomized, double-blind, placebo-controlled trial.
Silberstein SD; Stark SR; Lucas SM; Christie SN; Degryse RE; Turkel CC;
Mayo Clin Proc; 2005 Sep; 80(9):1126-37. PubMed ID: 16178492
[TBL] [Abstract][Full Text] [Related]
5. Botulinum toxin type A as migraine preventive treatment in patients previously failing oral prophylactic treatment due to compliance issues.
Cady R; Schreiber C
Headache; 2008 Jun; 48(6):900-13. PubMed ID: 18047501
[TBL] [Abstract][Full Text] [Related]
6. OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program.
Dodick DW; Turkel CC; DeGryse RE; Aurora SK; Silberstein SD; Lipton RB; Diener HC; Brin MF;
Headache; 2010 Jun; 50(6):921-36. PubMed ID: 20487038
[TBL] [Abstract][Full Text] [Related]
7. OnabotulinumtoxinA for treatment of chronic migraine: pooled analyses of the 56-week PREEMPT clinical program.
Aurora SK; Winner P; Freeman MC; Spierings EL; Heiring JO; DeGryse RE; VanDenburgh AM; Nolan ME; Turkel CC
Headache; 2011 Oct; 51(9):1358-73. PubMed ID: 21883197
[TBL] [Abstract][Full Text] [Related]
8. Botulinum Toxin Type A for the Treatment of Post-traumatic Headache: A Randomized, Placebo-Controlled, Cross-over Study.
Zirovich MD; Pangarkar SS; Manh C; Chen L; Vangala S; Elashoff DA; Izuchukwu IS
Mil Med; 2021 May; 186(5-6):493-499. PubMed ID: 33241323
[TBL] [Abstract][Full Text] [Related]
9. Predictors of response to botulinum toxin type A (BoNTA) in chronic daily headache.
Mathew NT; Kailasam J; Meadors L
Headache; 2008 Feb; 48(2):194-200. PubMed ID: 17868356
[TBL] [Abstract][Full Text] [Related]
10. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial.
Aurora SK; Dodick DW; Turkel CC; DeGryse RE; Silberstein SD; Lipton RB; Diener HC; Brin MF;
Cephalalgia; 2010 Jul; 30(7):793-803. PubMed ID: 20647170
[TBL] [Abstract][Full Text] [Related]
11. Botulinum toxin type A as an effective prophylactic treatment in primary headache disorders.
Blumenfeld A
Headache; 2003 Sep; 43(8):853-60. PubMed ID: 12940806
[TBL] [Abstract][Full Text] [Related]
12. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial.
Diener HC; Dodick DW; Aurora SK; Turkel CC; DeGryse RE; Lipton RB; Silberstein SD; Brin MF;
Cephalalgia; 2010 Jul; 30(7):804-14. PubMed ID: 20647171
[TBL] [Abstract][Full Text] [Related]
13. OnabotulinumtoxinA for treatment of chronic migraine: PREEMPT 24-week pooled subgroup analysis of patients who had acute headache medication overuse at baseline.
Silberstein SD; Blumenfeld AM; Cady RK; Turner IM; Lipton RB; Diener HC; Aurora SK; Sirimanne M; DeGryse RE; Turkel CC; Dodick DW
J Neurol Sci; 2013 Aug; 331(1-2):48-56. PubMed ID: 23790235
[TBL] [Abstract][Full Text] [Related]
14. Botulinum toxin A for chronic daily headache: a randomized, placebo-controlled, parallel design study.
Ondo WG; Vuong KD; Derman HS
Cephalalgia; 2004 Jan; 24(1):60-5. PubMed ID: 14687015
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of topiramate for the treatment of chronic migraine: a randomized, double-blind, placebo-controlled trial.
Silberstein SD; Lipton RB; Dodick DW; Freitag FG; Ramadan N; Mathew N; Brandes JL; Bigal M; Saper J; Ascher S; Jordan DM; Greenberg SJ; Hulihan J;
Headache; 2007 Feb; 47(2):170-80. PubMed ID: 17300356
[TBL] [Abstract][Full Text] [Related]
16. Botulinum toxin type-A in the prophylactic treatment of medication-overuse headache: a multicenter, double-blind, randomized, placebo-controlled, parallel group study.
Sandrini G; Perrotta A; Tassorelli C; Torelli P; Brighina F; Sances G; Nappi G
J Headache Pain; 2011 Aug; 12(4):427-33. PubMed ID: 21499747
[TBL] [Abstract][Full Text] [Related]
17. Concurrent onabotulinumtoxinA treatment of cervical dystonia and concomitant migraine.
Winner PK; Sadowsky CH; Martinez WC; Zuniga JA; Poulette A
Headache; 2012 Sep; 52(8):1219-25. PubMed ID: 22607530
[TBL] [Abstract][Full Text] [Related]
18. Long-term benefits of botulinum toxin type A (BOTOX) in chronic daily headache: a five-year long experience.
Farinelli I; Coloprisco G; De Filippis S; Martelletti P
J Headache Pain; 2006 Dec; 7(6):407-12. PubMed ID: 17149565
[TBL] [Abstract][Full Text] [Related]
19. Botulinum toxin type A in the prophylactic treatment of chronic tension-type headache: a multicentre, double-blind, randomized, placebo-controlled, parallel-group study.
Silberstein SD; Göbel H; Jensen R; Elkind AH; Degryse R; Walcott JM; Turkel C
Cephalalgia; 2006 Jul; 26(7):790-800. PubMed ID: 16776693
[TBL] [Abstract][Full Text] [Related]
20. Is botulinum toxin A effective for the treatment of plantar fasciitis?
Peterlein CD; Funk JF; Hölscher A; Schuh A; Placzek R
Clin J Pain; 2012 Jul; 28(6):527-33. PubMed ID: 22673486
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]